血清CA153、CEA和TPA联检在术前乳腺肿瘤鉴别诊断中的价值

Differential Diagnostic Value of Combined Detection of Serum CA153,CEA and TPA Levels in Patients with Breast Tumor

目的:本文探讨血清CA153、CEA和TPA联检在术前乳腺肿瘤鉴别诊断中价值,以期为乳腺癌患者即时手术提供帮助。方法:采用放射免疫分析,检测乳腺肿瘤患者和健康人群血清CA153、CEA和TPA含量。结果:在CA153、CEA和TPA血清学检测中,术前乳腺癌组与乳腺良性肿瘤和健康人群组表达水平存在明显差异。术前乳腺癌组阳性率:CA153为63.8%,CEA为22.4%,TPA为62.1%;术前乳腺癌组联检阳性率:CA153和CEA为69.8%,CA153和TPA为87.1%,三者联检为90.5%;术前乳腺癌组检测特异性:CA153为77.9%,CA153和CEA联检为77.9%,CA153和TPA联检为71.9%,三者联检为73.4%。结论:当CA153、CEA和TPA三者联检时,术前乳腺癌组诊断阳性率显著提高,阳性组特异性无明显下降,值得临床推广应用。

Objective To assess the differential diagnostic value of combined detection of serum CA153, CEA and TPA levels in patients with breast tumor. Methods Serum levels of CA153, CEA and TPA were measured with RIA in 269 patients with breast tumor and 150 controls. Results The serum levels of CA153, CEA and TPA in patients with breast cancer were significantly higher than those in the patients with benign breast tumor and controls. The positive rate of CA153 was 63.8% in the patients with breast cancer and that of CEA and TPA was 22.4% and 62.1% respectively with combined detection of CA153 and CEA, the positive rate was 69.8%, with CA153 and TPA combined, the positive rate was 87.1% ~ with the three marker combined, the positive rate was 90. 5%. The specificity was 77.9% with CA153, 77.9% with CA153 and CEA, 71.9% with CA153 and TPA, and 73.4% with all the three markers combined. Conclusion The positive rate was increased remarkably with combined detection of CA153, CEA and TPA, however the specificity was not much changed, so the combined detection was valuable for differential diagnosis.